• Akeso highlighted late-stage gains for ivonescimab, with a Phase III first-line biliary tract cancer study meeting the overall survival endpoint in August 2026.
• NMPA cleared ivonescimab with chemotherapy for first-line advanced squamous NSCLC in August 2026, adding a new commercial growth driver.
• Updated July 2026 data from the global Phase III HARMONi study showed overall survival improvement in EGFR-TKI-resistant NSCLC; the U.S. FDA is reviewing a BLA.
• R&D focus broadened to IO2.0 plus ADC2.0, with proprietary next-generation ADCs now in clinical development and combination Phase II studies underway.
• Pipeline expansion into immunology and CNS included AK139 in seven Phase II trials, AK150 in Phase I, and an ongoing Phase I study of mRNA vaccine AK154.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608272244PR_NEWS_USPR_____CN35850) on August 28, 2026, and is solely responsible for the information contained therein.